Steve Chmura, MD, PhD; Kathryn A. Winter, MS; Clifford Robinson, MD; et al.
free access
JAMA Oncol. 2021;7(6):845-852. doi:10.1001/jamaoncol.2021.0687
This phase 1 nonrandomized controlled trial uses data from NRG Oncology trials to investigate if ablation radiotherapy schedules designed for use with single tumors can be used in patients with oligometastases (2-4 tumors).
Claire Falandry, MD; Frédérique Rousseau, MD; Marie-Ange Mouret-Reynier, MD; et al.
free access
JAMA Oncol. 2021;7(6):853-861. doi:10.1001/jamaoncol.2021.0696
This randomized clinical trial compares the feasibility, efficacy, and safety of single-agent carboplatin every 3 weeks, weekly carboplatin鈥損aclitaxel, or conventional every-3-weeks carboplatin鈥損aclitaxel in vulnerable older patients with ovarian cancer.
-
Editorial
Vulnerable Older Adults With Ovarian Cancer鈥擳ime to Stop Undertreating
Stephanie L. Wethington, MD, MSc; Deborah K. Armstrong, MD; Stéphanie L. Gaillard, MD, PhD
JAMA Oncol
Ola Landgren, MD, PhD; Malin Hultcrantz, MD, PhD; Benjamin Diamond, MD; et al.
free access
JAMA Oncol. 2021;7(6):862-868. doi:10.1001/jamaoncol.2021.0611
This nonrandomized clinical trial assesses the safety and effectiveness of carfilzomib-lenalidomide-dexamethasone-daratumumab combination therapy for patients with newly diagnosed multiple myeloma, in the absence of high-dose melphalan chemotherapy and autologous hemopoietic cell transplant.
Peter S. Hall, PhD; Daniel Swinson, MD; David A. Cairns, PhD; et al.
open access
JAMA Oncol. 2021;7(6):869-877. doi:10.1001/jamaoncol.2021.0848
This randomized clinical trial assesses the efficacy of reduced-intensity chemotherapy for patient quality of life and cancer control in the treatment of older and/or frail patients.
Ronald C. Chen, MD, MPH; Kevin Haynes, PharmD, MSCE; Simo Du, MBBS, MHS; et al.
free access
JAMA Oncol. 2021;7(6):878-884. doi:10.1001/jamaoncol.2021.0884
This cohort study assesses the association of breast, colorectal, and prostate cancer screening rates with the COVID-19 pandemic and estimates the overall cancer screening deficit in 2020 across the US population.
Glen B. Taksler, PhD; Elisabeth F. P. Peterse, PhD; Isarah Willems, BSc; et al.
free access
JAMA Oncol. 2021;7(6):885-894. doi:10.1001/jamaoncol.2021.0952
This microsimulation study assesses optimal screening strategies in women who obtain some, but not all, US Preventive Services Task Force鈥搑ecommended cancer screenings.